The biological characteristics of patients with the epidermal growth factor receptor (EGFR) mutation differ greatly from those with wild-type EGFR; this leads to the use of different therapies and different clinical outcomes in patients with advanced (≥stage IIIB) lung adenocarcinoma. The gene discussed is EGFR; the disease is lung adenocarcinoma.